Arcus biosciences, inc. (RCUS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Collaboration and license revenue

1,750

-

-

-

1,750

-

-

-

-

-

-

-

-

Collaboration and license revenue

-

-

1,750

1,750

-

1,562

4,291

1,250

1,250

-

163

-

-

Operating expenses:
Research and development

23,142

20,687

17,241

24,999

15,554

11,436

12,859

13,699

11,652

12,145

21,435

7,834

5,804

General and administrative

7,008

6,590

7,758

5,911

4,969

3,610

3,577

3,450

2,929

2,448

1,862

1,830

1,496

Total operating expenses

30,150

27,277

24,999

30,910

20,523

15,046

16,436

17,149

14,581

14,593

23,297

9,664

7,300

Loss from operations

-28,400

-17,527

-23,249

-29,160

-18,773

-13,484

-12,145

-15,899

-13,331

-13,343

-23,134

-9,664

-7,300

Non-operating income (expense):
Non-operating income (expense):
Interest and other income, net

647

931

1,254

1,482

1,534

1,512

1,519

1,288

603

-

-

-

-

Gain on deemed sale from equity method investee

482

0

0

0

0

-

0

1,229

-

-

-

-

-

Share of loss from equity method investee

-482

-2

-357

-412

-431

-323

-186

-151

-226

-

-

-

-

Total non-operating income, net

647

929

897

1,070

1,103

1,189

1,333

2,366

377

133

12

114

100

Net loss

-27,753

-16,598

-22,352

-28,090

-17,670

-12,295

-10,812

-13,533

-12,954

-13,210

-23,122

-9,550

-7,200

Other comprehensive income

224

10

-59

84

136

1

-25

14

-55

-33

14

11

-8

Comprehensive loss

-27,529

-16,588

-22,411

-28,006

-17,534

-12,294

-10,837

-13,519

-13,009

-13,243

-23,108

-9,539

-7,208

Net loss per share, basic and diluted

-0.63

-0.37

-0.51

-0.64

-0.41

0.51

-0.25

-0.32

-1.37

-6.57

-11.86

-5.64

-4.96

Weighted-average number of shares used to compute basic and diluted net loss per share

44,282

44,058

43,939

43,797

43,508

43,612

42,838

42,533

9,488

2,218

1,949

1,693

1,452